Phase 2Terminated

A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects (ACT-AKI)

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of AC607 for the Treatment of Acute Kidney Injury in Cardiac Surgery Subjects

Sponsor
AlloCure Inc. (Industry)
Enrollment
156 enrolled
Conditions
Acute Kidney Injury
Interventions
AC607; Vehicle Only
Ages
adults, older adults
Registry
NCT01602328

Full record on ClinicalTrials.gov

From the registry

Subjects entering the study will have undergone cardiac surgery. Those who experience kidney injury within 48 hours of their surgery will be enrolled into the study. Once enrolled, subjects will receive a single administration of AC607 or placebo. Kidney recovery will be evaluated over the subsequent 30 days and death or the need for dialysis will be evaluated within 90 days of dosing. After 90 days (evaluation period), subjects will enter a 3-year extension phase of the study to monitor safety and long-term outcomes (follow-up period).

Primary outcomes

  • Time to Kidney Recovery defined as a post-operative serum creatinine return to pre-operative baseline values.

History

  1. Study completion

  2. Last registry update

  3. Primary completion

  4. Started

  5. Registered